2021 ASCRS Annual Meeting Announcement
Registration is Open
Registration and Housing for the 2021 ASCRS and ASOA Annual Meetings is Open!
Register now to attend the 2021 ASCRS Annual Meeting, featuring:
- Essential education and the latest in clinical techniques
- Inspiring speakers, expert faculty, and distinguished lecturers
- An Exhibit Hall with the latest industry trends from more than 200 companies
- Unparalleled opportunities to connect with friends, colleagues, and mentors
- ASOA practice management education for all members of the practice
The Early Bird Registration deadline is April 30 for the meeting being held in person July 23–27 in Las Vegas, Nevada!
FDA: OPhthalmic drugs and devices
ASCRS advocates to ensure our members have timely access to innovative drugs and devices, access to compounded medications, and key information on drug and device recalls.
ASCRS supports the Food and Drug Administration’s (FDA) efforts to ensure the safety and sterility of compounded and repackaged drugs. Most recently, ASCRS has advocated for revised policies that seek to improve physicians’ access to compounded drugs for office-use to treat patients that present with emergent conditions. Additionally, we have been successful in advocating for continued access to repackaged biologics, such as Avastin. However, we remain concerned with the FDA’s implementation of the compounding provisions of the Drug Quality and Security Act (DQSA) and its impact on the availability of compounded drug products. Specifically, we are concerned that current FDA polices do not provide ophthalmologists with a pathway to secure drugs needed for office-use for patients who present an emergent condition. Additionally, the FDA’s final guidance to only include substances on the 503B Bulks List if there is no FDA-approved drug available and if there is a clinical need for the compounded drug, may significantly limit patient and physician access to compounded drugs.